• 分类：最新消息
• 作者：华讯知识产权
• 来源：
• 发布时间：2021-03-11 15:27
• 访问量：

【概要描述】Gamma Frequency Neuromodulation for Alzheimer's Disease Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly worldwide. AD has a profound negative impact not only on patients, but also on their families, communities, and countries. In the field of AD therapy, since 2003, the US FDA has not approved any innovative drugs for the treatment of AD. However, scientists have never stopped exploring innovative treatments for AD.  On March 09, Cognito Therapeutics announced at 2021 AD/PD Conference held online that the company’s innovative digital therapy for the treatment of AD through visual and auditory stimulation achieved positive results in Phase 2 clinical study. The reported Phase 2 data showed that Gamma frequency neuromodulation was safe and well tolerated. Over the 6-month period, patients in the treatment group exhibited a significant 84% slowing of functional decline in ADCS-ADL scores and a significant 83% slowing in memory and cognitive decline as measured by MMSE scores, compared to patients in the placebo group. Patients in the treatment group also demonstrated a significant 61% reduction in whole brain atrophy and volumetric loss associated with AD, compared to placebo group patients at 6 months, indicating a potential disease modifying effect. It is worth mentioning that, Cognito Therapeutics’ licensed proprietary gamma frequency neuromodulation platform technology, is a non-invasive therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases, that is developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden. Professor Tsai is an internationally renowned neuroscientist, and her team, published a paper in the top scientific journal "Nature" as early as 2016, showing that in a mouse model of Alzheimer's disease, using LED lights to emit flashes of special frequency can reduce Amyloid deposition in the mouse brain. Amyloid deposition is one of the hallmark features of the AD brain, and it is also the target of many drug therapies currently under study. “Our approach has translated into clinical proof of concept by successfully achieving statistically significant results in AD, with a potential for disease modification due to significant reduction of cerebral atrophy and volumetric loss,” said Dr. Tom Megerian, Chief Medical Officer, Cognito Therapeutics, “If these results are replicated in our larger, pivotal trial, this will represent a huge medical breakthrough in Alzheimer’s research.”